China Kadoorie Biobank (CKB) prospective study of 0.5 million adults (360G-Wellcome-202922_Z_16_Z)
CKB is a blood-based prospective study of 512,000 adults, recruited during 2004-8 from 10 diverse regions of China, with extensive data collected at baseline and subsequent resurveys using questionnaires, physical measurements, and stored biological samples. By 1.1.2014, 25,000 deaths and ~1.5M coded disease events had been recorded among participants, through linkages with death and disease registries and national health insurance systems. Genome-wide data are being generated (first phase: ~100,000 participants by Q3/2016), along with blood biochemistry and multi-omics data for nested case-control studies of specific diseases. We are seeking renewal of two-year funding to support core activities to maintain, enhance and share the resource through: (i) continued follow-up of cause-specific morbidity and mortality and hospital records through electronic linkage to health insurance systems; (ii) validation, clinical adjudication and detailed sub-phenotyping for selected diseases (e.g. stroke, IHD, cancer); (iii) maintenance and management of extensive and uniquely large and complex datasets; (iv) enhancement of collaboration and data sharing with the wider scientific community; and (v) maintenance and development of administrative and technological systems underpinning the infrastructure, sample storage and resurvey. The CKB resource will improve our understanding of disease aetiology, risk prediction and development of new therapies, and should benefit populations worldwide.
£1,737,405 16 Jun 2016